These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 6509007)

  • 1. Ocular changes in patients undergoing long-term desferrioxamine treatment.
    Arden GB; Wonke B; Kennedy C; Huehns ER
    Br J Ophthalmol; 1984 Dec; 68(12):873-7. PubMed ID: 6509007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depletion of trace elements and acute ocular toxicity induced by desferrioxamine in patients with thalassaemia.
    De Virgiliis S; Congia M; Turco MP; Frau F; Dessi C; Argiolu F; Sorcinelli R; Sitzia A; Cao A
    Arch Dis Child; 1988 Mar; 63(3):250-5. PubMed ID: 3355204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Desferrioxamine-related ocular toxicity: a case report.
    Simon S; Athanasiov PA; Jain R; Raymond G; Gilhotra JS
    Indian J Ophthalmol; 2012 Jul; 60(4):315-7. PubMed ID: 22824603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tinnitus in a patient with beta-thalassaemia intermedia on long-term treatment with desferrioxamine.
    Marsh MN; Holbrook IB; Clark C; Shaffer JL
    Postgrad Med J; 1981 Sep; 57(671):582-4. PubMed ID: 7329898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hearing loss attributed to desferrioxamine in patients with beta-thalassaemia major.
    Barratt PS; Toogood IR
    Med J Aust; 1987 Aug; 147(4):177-9. PubMed ID: 3657630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ocular findings in beta-thalassemia.
    Sorcinelli R; Sitzia A; Figus A; Lai ME
    Metab Pediatr Syst Ophthalmol (1985); 1990; 13(1):23-5. PubMed ID: 2370833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The echocardiography in thalassemia major (author's transl)].
    Musumeci S; Schiliro G; Romeo MA; Di Gregorio F; Russo G; Scibilia G
    Pediatr Med Chir; 1981; 3(2-3):219-22. PubMed ID: 6211659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron status in thalassemia major patients after long-term subcutaneous desferrioxamine.
    Kontopoulou-Griva I; Hatzidimitriou-Papazacharia K; Spiliotopoulou J; Tsagarakis N; Digenopoulou E
    Birth Defects Orig Artic Ser; 1988; 23(5B):111-6. PubMed ID: 3390532
    [No Abstract]   [Full Text] [Related]  

  • 9. Early iron overload in beta-thalassaemia major: when to start chelation therapy?
    Fargion S; Taddei MT; Gabutti V; Piga A; Di Palma A; Capra L; Fontanelli G; Avanzini A
    Arch Dis Child; 1982 Dec; 57(12):929-33. PubMed ID: 7181522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ocular and auditory toxicity of long-term, high-dose subcutaneous deferoxamine therapy.
    Orton RB; de Veber LL; Sulh HM
    Can J Ophthalmol; 1985 Jun; 20(4):153-6. PubMed ID: 4052864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hearing loss and desferrioxamine in homozygous beta-thalassemia.
    Albera R; Pia F; Morra B; Lacilla M; Bianco L; Gabutti V; Piga A
    Audiology; 1988; 27(4):207-14. PubMed ID: 3190562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Electroretinographic and visual-evoked potential abnormalities in patients with beta-thalassemia major.
    Gelmi C; Borgna-Pignatti C; Franchin S; Tacchini M; Trimarchi F
    Ophthalmologica; 1988; 196(1):29-34. PubMed ID: 3347468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lens opacities in thalassemia.
    Bloomfield SE; Markenson AL; Miller DR; Peterson CM
    J Pediatr Ophthalmol Strabismus; 1978; 15(3):154-6. PubMed ID: 739345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iron state and hepatic disease in patients with thalassaemia major, treated with long term subcutaneous desferrioxamine.
    Aldouri MA; Wonke B; Hoffbrand AV; Flynn DM; Laulicht M; Fenton LA; Scheuer PJ; Kibbler CC; Allwood CA; Brown D
    J Clin Pathol; 1987 Nov; 40(11):1353-9. PubMed ID: 3121679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Desferrioxamine related maculopathy: a case report.
    Arora A; Wren S; Gregory Evans K
    Am J Hematol; 2004 Aug; 76(4):386-8. PubMed ID: 15282675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucose tolerance and chelation therapy in patients with thalassaemia major.
    Capra L; Atti G; De Sanctis V; Candini G
    Haematologica; 1983; 68(1):63-8. PubMed ID: 6404709
    [No Abstract]   [Full Text] [Related]  

  • 17. Quality of life in transfusion-dependent thalassaemia patients on desferrioxamine treatment.
    Dahlui M; Hishamshah MI; Rahman AJ; Aljunid SM
    Singapore Med J; 2009 Aug; 50(8):794-9. PubMed ID: 19710979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute renal insufficiency occurring during intravenous desferrioxamine therapy.
    Batey R; Scott J; Jain S; Sherlock S
    Scand J Haematol; 1979 Mar; 22(3):277-9. PubMed ID: 451459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous desferrioxamine: the effect of three years' treatment on liver, iron, serum ferritin, and comments on echocardiography.
    Flynn DM; Hoffbrand AV; Politis D
    Birth Defects Orig Artic Ser; 1982; 18(7):347-53. PubMed ID: 6819017
    [No Abstract]   [Full Text] [Related]  

  • 20. [Audiologic evaluation of patients with thalassemic syndromes treated with desferrioxamine B].
    Gaini RM; Moretti E; Boffa C; Terzoli S; Carnelli V
    Pediatr Med Chir; 1988; 10(5):503-4. PubMed ID: 3241755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.